Bayer's heart and kidney drug Kerendia can also help patients with hypertensive nephropathy, a type of kidney damage that can result from chronic high blood pressure. A subgroup analysis of the pivotal Phase III FIND-CKD study showed, according to the company on Sunday, that the active ingredient finerenone in Kerendia, in addition to standard therapy, slowed the decline in kidney function in patients with hypertensive nephropathy compared with a placebo.
Bayer said this on Sunday on the sidelines of the European Society of Cardiology (ESC) congress in Munich. Compared with a placebo, the combined renal and cardiovascular risk was also reduced. To date, only a few guideline-recommended treatment options have been available for the affected patient group.
Kerendia (sometimes also marketed as Firialta) is already used in many countries to treat chronic kidney disease (CKD) in combination with type 2 diabetes (T2D), as well as heart failure. Finerenone is currently not approved for the treatment of non-diabetic CKD.
The still relatively new drug is among the growth drivers of the pharmaceutical division. In the first half of 2026 alone, revenue from Kerendia rose 75 percent year on year to €603m./mis/zb
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.